Paper39200006
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martín-Cerezuela M and 10 others. Antibiotics (Basel), 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety. Papers, record 39200006. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39200006
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37808914 | Mucormycosis in 2023: an update on pathogenesis and management. | Front Cell Infect Microbiol | 2023 | https://conductscience.org/library/papers/37808914 | PubMed |
| 2 | 31767725 | Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/31767725 | PubMed |
| 3 | 33922419 | Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole. | Antibiotics (Basel) | 2021 | https://conductscience.org/library/papers/33922419 | PubMed |
| 4 | 33333012 | Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. | Lancet Infect Dis | 2021 | https://conductscience.org/library/papers/33333012 | PubMed |
| 5 | 36978342 | Antimicrobial Pharmacokinetics and Pharmacodynamics in Critical Care: Adjusting the Dose in Extracorporeal Circulation and to Prevent the Genesis of Multiresistant Bacteria. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/36978342 | PubMed |
| 6 | 29544767 | Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. | Clin Microbiol Infect | 2018 | https://conductscience.org/library/papers/29544767 | PubMed |
| 7 | 37508181 | Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/37508181 | PubMed |
| 8 | 32535847 | Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. | J Pharmacokinet Pharmacodyn | 2020 | https://conductscience.org/library/papers/32535847 | PubMed |
| 9 | 35726095 | Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. | J Antimicrob Chemother | 2022 | https://conductscience.org/library/papers/35726095 | PubMed |
| 10 | 31119272 | Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. | J Antimicrob Chemother | 2019 | https://conductscience.org/library/papers/31119272 | PubMed |
| 11 | 28355463 | Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/28355463 | PubMed |
| 12 | 29725999 | Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. | Clin Pharmacokinet | 2018 | https://conductscience.org/library/papers/29725999 | PubMed |
| 13 | 26684607 | Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. | Lancet | 2016 | https://conductscience.org/library/papers/26684607 | PubMed |
| 14 | 33361296 | Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/33361296 | PubMed |
| 15 | 37700457 | Clinical and demographic factors affecting trough levels of isavuconazole in critically ill patients with or without COVID-19. | Mycoses | 2023 | https://conductscience.org/library/papers/37700457 | PubMed |
| 16 | 35535740 | Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis. | Mycoses | 2022 | https://conductscience.org/library/papers/35535740 | PubMed |
| 17 | 29735569 | Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29735569 | PubMed |
| 18 | 36183212 | Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics in critically ill patients. | Farm Hosp | 2022 | https://conductscience.org/library/papers/36183212 | PubMed |
| 19 | 30851209 | Impact of voriconazole plasma concentrations on treatment response in critically ill patients. | J Clin Pharm Ther | 2019 | https://conductscience.org/library/papers/30851209 | PubMed |
| 20 | 36354913 | Survival Outcome of Empirical Antifungal Therapy and the Value of Early Initiation: A Review of the Last Decade. | J Fungi (Basel) | 2022 | https://conductscience.org/library/papers/36354913 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42984876 | Pharmacokinetic and pharmacodynamic strategies to optimize antifungal therapy, prevent resistance and minimize treatment failure. | JAC Antimicrob Resist | 2026 | https://conductscience.org/library/papers/42984876 | PubMed |
| 42903265 | Population pharmacokinetic model library for isavuconazole: development and quality control. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42903265 | PubMed |
| 42797225 | Pharmacokinetics of Isavuconazole in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO) Support: A Prospective Exploratory Observational Study. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42797225 | PubMed |
| 42394820 | Exploratory model-based optimizing isavuconazole dosing regimens for Aspergillus spp. in adult patients according to serum albumin levels: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42394820 | PubMed |
| 42088097 | Characterization of isavuconazole pharmacokinetics and pharmacodynamics in a real-life cohort. | JAC Antimicrob Resist | 2026 | https://conductscience.org/library/papers/42088097 | PubMed |
| 41919159 | Therapeutic drug monitoring-guided optimization of isavuconazole dose for ICU patients with refractory pulmonary aspergillosis: case report. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/41919159 | PubMed |
| 41515529 | Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/41515529 | PubMed |
| 41311305 | Management of Invasive Pulmonary Aspergillosis in Intensive Care Units: Guidelines From the Fungal Infection Network of Switzerland (FUNGINOS). | Mycoses | 2025 | https://conductscience.org/library/papers/41311305 | PubMed |
| 41059267 | Use of isavuconazole in critically ill patients in intensive care units: a prospective, observational, multicentre, cohort study. | JAC Antimicrob Resist | 2025 | https://conductscience.org/library/papers/41059267 | PubMed |
| 41024947 | Antimicrobial dosing considerations in critically ill patients with acute kidney injury: A review. | World J Nephrol | 2025 | https://conductscience.org/library/papers/41024947 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39200006
GET https://conductscience.org/api/papers/v1/39200006/references?page=2